Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera

Jie Hu; Xiao-yu Wei; Jin Xiang; Pai Peng; Feng-li Xu; Kang Wu; Fei-yang Luo; Ai-shun Jin; Liang Fang; Bei-zhong Liu; Kai Wang; Ni Tang; Ai-Long Huang

doi:10.1016/j.gendis.2021.11.007

您当前的位置：

首页 >

文章列表页 >

Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera

Full-length article | 更新时间：2022-08-11

- Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera
- Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera
- Genes & Diseases 2022年9卷第5期
- 作者机构：
  
  1. Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University,Chongqing,PR China,400010
  2. Yong-Chuan Hospital, Chongqing Medical University,Chongqing,PR China,402177
  3. Department of Immunology, College of Basic Medicine, Chongqing Medical University,Chongqing,PR China,400016
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2021.11.007
  中图分类号：
- 纸质出版日期：2022，
  
  网络出版日期：2022-9-1，
扫描看全文
Jie Hu, Xiao-yu Wei, Jin Xiang, 等. Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera[J]. Genes & Diseases, 2022,9(5).

Jie Hu, Xiao-yu Wei, Jin Xiang, et al. Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera[J]. Genes & Diseases, 2022,9(5).
Jie Hu, Xiao-yu Wei, Jin Xiang, 等. Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera[J]. Genes & Diseases, 2022,9(5). DOI： 10.1016/j.gendis.2021.11.007.

Jie Hu, Xiao-yu Wei, Jin Xiang, et al. Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera[J]. Genes & Diseases, 2022,9(5). DOI： 10.1016/j.gendis.2021.11.007.

摘要

Abstract

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Spike protein that mediates coronavirus entry into host cells is a major target for COVID-19 vaccines and antibody therapeutics. However

multiple variants of SARS-CoV-2 have emerged

which may potentially compromise vaccine effectiveness. Using a pseudovirus-based assay

we evaluated SARS-CoV-2 cell entry mediated by the viral Spike B.1.617 and B.1.1.7 variants. We also compared the neutralization ability of monoclonal antibodies from convalescent sera and neutralizing antibodies (NAbs) elicited by CoronaVac (inactivated vaccine) and ZF2001 (RBD-subunit vaccine) against B.1.617 and B.1.1.7 variants. Our results showed that

compared to D614G and B.1.1.7 variants

B.1.617 shows enhanced viral entry and membrane fusion

as well as more resistant to antibody neutralization. These findings have important implications for understanding viral infectivity and for immunization policy against SARS-CoV-2 variants.

关键词

Keywords

CoronavirusImmune escapeMutationNeutralizing antibodiesSARS-Cov-2VaccineViral entry

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2

Unclear but present danger: An asymptomatic SARS-CoV-2 carrier

CRISPR/Cas9 system and its applications in nervous system diseases

HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies

COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery